Skip to main navigation Skip to search Skip to main content

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/46854/MonH-2018-153621
NMA SSA Reference Number: SSA/46854/MonH-2018-153865
Monash Health Ref: RES-18-0000-438A
StatusFinished
Effective start/end date29/11/18 → 28/11/23

Clinical Trial Phase

  • Phase I
  • Phase II